Alpha Teknova (NASDAQ:TKNO – Get Rating) released its earnings results on Wednesday. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.03, Fidelity Earnings reports. Alpha Teknova had a negative net margin of 37.59% and a negative return on equity of 10.02%. Alpha Teknova updated its FY 2022 guidance to EPS.
Shares of TKNO stock opened at $12.86 on Friday. The stock’s fifty day simple moving average is $13.84 and its 200-day simple moving average is $17.04. The company has a current ratio of 13.07, a quick ratio of 12.37 and a debt-to-equity ratio of 0.08. Alpha Teknova has a 1-year low of $8.51 and a 1-year high of $30.89.
Hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its stake in Alpha Teknova by 7.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 18,357 shares of the company’s stock valued at $376,000 after purchasing an additional 1,224 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Alpha Teknova by 27.9% during the first quarter. JPMorgan Chase & Co. now owns 6,571 shares of the company’s stock worth $91,000 after purchasing an additional 1,435 shares during the period. Citigroup Inc. increased its stake in Alpha Teknova by 191.3% in the fourth quarter. Citigroup Inc. now owns 2,578 shares of the company’s stock valued at $53,000 after acquiring an additional 1,693 shares during the last quarter. Bank of America Corp DE increased its stake in Alpha Teknova by 605.9% in the fourth quarter. Bank of America Corp DE now owns 4,285 shares of the company’s stock valued at $87,000 after acquiring an additional 3,678 shares during the last quarter. Finally, California State Teachers Retirement System bought a new position in Alpha Teknova in the third quarter valued at approximately $94,000. Hedge funds and other institutional investors own 25.51% of the company’s stock.
About Alpha Teknova (Get Rating)
Alpha Teknova, Inc provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
- Get a free copy of the StockNews.com research report on Alpha Teknova (TKNO)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.